 Eagle Pharmaceuticals Inc NASDAQ: EGRX has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product, Landiolol, in the U.S. Landiolol, a hospital emergency use product, is approved in Europe to treat non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias. 